论文部分内容阅读
目的:观察前列地尔(凯时)联合川芎嗪注射液(川青)治疗糖尿病肾病的临床疗效,探讨其降低尿蛋白,减轻肾损害的机制。方法:收集早期2型糖尿病患者120例,随机分成川芎嗪组(40例)、前列地尔组(40例)和联合治疗组(40例)。全部病例进行临床观察2周,分别比较三组血肌酐(Cr)、尿素氮(BUN)、24 h尿蛋白定量治疗前后的变化。结果:治疗2周后,联合治疗组降低24 h尿蛋白定量的作用优于川芎嗪组和前列地尔组差异有统计学意义(P<0.05)。前列地尔组和川芎嗪组比较,差异有统计学意义(P<0.05)。结论:静脉应用前列地尔联合川芎嗪注射液能够降低糖尿病肾病患者尿蛋白,延缓糖尿病肾病的进展,值得临床推广。
Objective: To observe the clinical efficacy of alprostadil combined with ligustrazine (Chuanqing) in the treatment of diabetic nephropathy, and to explore its mechanism of reducing urinary protein and reducing renal damage. Methods: One hundred and twenty patients with early type 2 diabetes mellitus were collected and randomly divided into ligustrazine group (40 cases), alprostadil group (40 cases) and combination therapy group (40 cases). All cases were observed for 2 weeks, and the changes of serum creatinine (Cr), blood urea nitrogen (BUN) and 24 h urine protein before and after treatment were compared respectively. Results: After 2 weeks of treatment, the effect of reducing 24 h urinary protein in combination therapy group was better than that of ligustrazine group and alprostadil group (P <0.05). Alprostadil group and ligustrazine group, the difference was statistically significant (P <0.05). Conclusion: The intravenous application of alprostadil and ligustrazine injection can reduce the urinary protein in patients with diabetic nephropathy and delay the progression of diabetic nephropathy, which deserves clinical promotion.